Omega-3 fatty acids — primarily EPA and DHA from marine sources — are essential fats with a substantial but uneven evidence base. The clearest clinical effect is triglyceride reduction, while cardiovascular event reduction and cognition claims depend heavily on dose, formulation, baseline risk and whether the product is prescription EPA or standard mixed fish oil. Most people consuming a Western diet do not eat enough oily fish to meet recommended intakes.
Omega-3s (EPA and DHA) are most defensible for people with low fish intake or elevated triglycerides. Prescription high-dose EPA has cardiovascular outcomes evidence in selected high-risk patients, but standard OTC fish oil has mixed trial results for cardiovascular prevention and cognition. ALA from flaxseed is a poor substitute — the conversion rate to EPA/DHA is very low.
Each row grades the claimed effect by strength of human evidence, not mechanism or marketing.
Supported by cardiology and nutrition bodies for people with elevated triglycerides and as a dietary complement for those low in fish intake. Prescription-dose EPA (Vascepa) is approved for cardiovascular risk reduction in selected high-risk patients.
Often promoted as a daily universal supplement with near-magic properties for the brain, joints, mood and ageing.
The triglyceride evidence is solid. Cardiovascular event reduction at standard OTC doses is much less clear than prescription EPA data. Mental health signal exists but requires more replication. Quality of product (oxidation, purity) is a real-world issue often ignored.
EPA and DHA are the biologically active omega-3s — not ALA from plant sources like flaxseed, whose conversion rate to EPA/DHA is under 10% in humans.
Algae oil is a sustainable, fish-free source of DHA and EPA — appropriate for vegetarians and vegans.
Fish oil oxidises readily — rancid oil may cause harm rather than benefit. Smell, form (triglyceride vs ethyl ester) and storage matter.
The EPA-to-DHA ratio matters for specific applications: EPA is more relevant for mood; DHA is the dominant structural fat in the brain.
High-dose prescription EPA (4 g/day icosapentaenoic acid) has cardiovascular trial evidence in selected high-risk patients. This is different from standard OTC fish oil.
Mechanism is not outcome. Each mechanism is labelled by how far it has been validated in humans.
EPA and DHA are incorporated into cell membranes, altering fluidity and the production of signalling molecules (eicosanoids, resolvins, protectins) that modulate inflammation.
Omega-3s compete with arachidonic acid (an omega-6) in eicosanoid synthesis, shifting the balance toward less inflammatory prostaglandins and leukotrienes.
EPA and DHA reduce VLDL secretion from the liver and increase triglyceride clearance — the mechanism behind their lipid-lowering effects.
DHA is the dominant fatty acid in neural membranes and synapses. Low DHA status is associated with cognitive decline, but trials have not established routine supplementation as dementia prevention.
Generally safe at 1–3 g EPA+DHA daily. GRAS status in the US. Long-term safety well-established at standard doses.
This page is educational and not medical advice. If you take blood thinners or have a clotting disorder, discuss omega-3 supplementation with a clinician.
A small, curated set — not a literature dump. Each reference comes with a single-line takeaway.
4 g/day EPA (icosapentaenoic acid) reduced major cardiovascular events by 25% in high-risk patients. Results remain debated due to mineral oil placebo.
Omega-3 supplementation was associated with modest reduction in depressive symptoms, particularly with higher EPA ratios.
Omega-3s consistently reduce liver triglycerides and improve other metabolic markers in fatty liver disease contexts.
Modest reductions in cardiovascular mortality seen; effects on non-fatal MI and stroke were less consistent.